Financings Routine −

Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares

Thiogenesis Upsizes Cystinosis Cash Raise as Clinical Runway Extends, But Dilution Weighs on Near-Term Sentiment

By The Northwire Desk — AI Analysis Jun 01, 2026 · 14:50 TTI · 0.6 Thiogenesis Therapeutics, Corp.

Executive Summary

Thiogenesis Therapeutics announced the upsize of its previously announced non-brokered private placement from 16 million to approximately 18 million common shares.
The offering is priced at $0.50 per share, generating approximately $9 million in gross proceeds.
Proceeds will fund the clinical development of TTI-0102, including an investigator-initiated study in cystinosis and a Phase 2a clinical study in Leigh syndrome, alongside manufacturing scale-up and regulatory engagement.
The transaction received conditional acceptance from the TSX Venture Exchange, with closing expected later in the week.
This follows the initial announcement on May 11, 2026, which targeted up to 16 million shares for $8 million at the same $0.50 price point.

Material Impact

The upsize reflects strong institutional and retail demand for the company's clinical pipeline, which is a positive signal of investor confidence.
However, the financing is dilutive. Issuing 18 million shares at $0.50 represents a ~16.7% discount to the recent trading range of $0.56-$0.60, and likely a significant percentage of the fully diluted share count.
The capital raise extends the cash runway into late 2026 or early 2027, reducing immediate near-term dilution risk but confirming the company's reliance on periodic equity financings to fund pre-revenue clinical development.
The news is a routine follow-up to the May announcement. It does not introduce new clinical data, regulatory milestones, or strategic partnerships that would materially alter the company's valuation trajectory.

TTI · Price

Company Overview

Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing TTI-0102, a novel cysteamine-based disulfide prodrug.
TTI-0102 is designed to deliver sustained cysteamine exposure with lower peak plasma levels, aiming for once-daily oral dosing and improved gastrointestinal tolerability compared to existing therapies like Cystagon® and Procysbi®.
The pipeline targets mitochondrial and metabolic diseases, with active development in MELAS (Phase 2), Leigh syndrome spectrum (Phase 2a), and nephropathic cystinosis (Phase 3 planning).
Interim Phase 2 MELAS data presented in January 2026 showed statistically significant fatigue improvement and favorable PK/PD profiles, supporting dose optimization for upcoming trials.

More from Thiogenesis Therapeutics, Corp.